The immuno-oncology market has grown at a compound rate of 10%, from $57 billion to $69 billion in 2021. It is expected to reach around $98 billion by 2025. This is a highly competitive market, so companies in this sector have to innovate rapidly by creating novel drugs and therapies.
Montana’s Inimmune recently made the top-20 list.
Golden Helix is laser-focused on providing innovative NGS analysis software to their customers. Founded in 1998, they have been at the forefront of the genomic revolution while empowering the world’s top clinicians and researchers to derive meaning from their increasing volume of genetic data. As reported in a recent article in CIO Views, the company is also recognized as a top biotech company worldwide, equally as dedicated to fostering a healthy workplace and supporting each of their employees.
A Montana State University undergraduate has been admitted to a prestigious European graduate program where she will advance her research in disease prevention and other applications of the growing field of bioinformatics.
Beginning with cannabis, the Missoula, MT based company is creating a self-contained and portable product that can detect impairment in real-time. The product will be sold to law enforcement agencies, and businesses with safety-critical employees.
Tonix Pharmaceuticals will collaborate with Massachusetts General Hospital to further develop a humanized monoclonal antibody, TNX-1500, to prevent organ transplant rejection, specifically in kidney transplants.
Potential Uses Include: Biomarker of Immunity to SARS-CoV-2; Personalized Approach to Timing COVID-19 Vaccine Boosters; Public Health Surveillance; and Serving as an Endpoint for COVID-19 Vaccine Trials
Their ideas included a virtual reality textbook, a new building material, a food incubator, a device to assist construction workers, various software solutions and a student-focused professional networking platform.
As research programs grow at the University of Montana, a team of vaccine scientists are making headway into long-term COVID-19 prevention and clinical trials for an opioid vaccine.
With new labeling requirements, bioengineering entered consumer consciousness in a new way this year—but people are learning the benefits, according to Sarah Gallo, BIO’s VP of Agriculture and Environment, in this podcast.